Department of Nuclear Medicine, Medical University of Vienna, Austria.
Eur J Radiol. 2010 Mar;73(3):461-9. doi: 10.1016/j.ejrad.2009.12.022. Epub 2010 Feb 24.
The presented review provides general background on PET radiopharmaceuticals for oncological applications. Special emphasis is put on radiopharmacological, radiochemical and regulatory aspects. This review is not meant to give details on all different PET tracers in depth but to provide insights into the general principles coming along with their preparation and use. The PET tracer plays a pivotal role because it provides the basis both for image quality and clinical interpretation. It is composed of the radionuclide (signaller) and the molecular vehicle which determines the (bio-)chemical properties (e.g. binding characteristics, metabolism, elimination rate).
本文综述了用于肿瘤学应用的正电子发射断层扫描(PET)放射性药物的一般背景。特别强调了放射性药物、放射化学和监管方面的内容。本综述的目的不是详细介绍所有不同的 PET 示踪剂,而是深入了解其制备和使用所涉及的一般原理。PET 示踪剂起着至关重要的作用,因为它为图像质量和临床解释提供了基础。它由放射性核素(信号物)和分子载体组成,决定了(生物)化学性质(例如结合特性、代谢、消除率)。